Todd Vanderah, PhD

Department Head, Pharmacology
Professor, Anesthesiology
Professor, Neurology
Professor, Neuroscience - GIDP
Professor, Pharmacology
Professor, Physiological Sciences - GIDP
Phone Number: 
(520) 626-7801
(520) 626-4479

UACC Information

UACC Organizational Unit(s): 
Professional Bio: 

Dr. Vanderah is Head and Professor of Pharmacology, and is a Professor in the Departments of Neurology and Anesthesiology. His research interests include mechanisms of cancer pain, neuronal integration in pain pathways, neurochemical release during conditions of neuropathy, neuronal plasticity, opioid receptor pharmacology, and novel targets for drug discovery. He is author of over 135 original research articles.

Research Information

Research Program: 
Cancer Biology
Member Status: 
Research Member
Year of Membership Acceptance: 
University of Arizona
Department of Pharmacology
Selected Publications: 

Dr. Vanderah's NCBI bibliography

  1. Lee YS, Muthu D, Hall SM, Ramos-Colon C, Rankin D, Hu J, Sandweiss AJ, De Felice M, Xie JY, Vanderah TW, Porreca F, Lai J, Hruby VJ. Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord. J. Am. Chem. Soc. 2014;136:6608–6616.
  2. Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YS, Hruby VJ, Vardanyan RS, Vanderah TW. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Life Sci. 2013;93:1010–1016.
  3. Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW. Cancer-induced bone pain: Mechanisms and models. Neurosci. Lett. 2013;557 Pt A:52–59.
  4. Slosky LM, Thompson BJ, Sanchez-Covarrubias L, Zhang Y, Laracuente M-L, Vanderah TW, Ronaldson PT, Davis TP. Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanism. Mol. Pharmacol. 2013;84:774–786.
  5. Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW. Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J. Pharmacol. Exp. Ther. 2013;347:7–19.
  6. Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma S-W, Vanderah TW, Lai J, Porreca F, Hruby VJ. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg. Med. Chem. Lett. 2013;23:4975–4978.
  7. Petrov RR, Lee YS, Vardanyan RS, Liu L, Ma S, Davis P, Lai J, Porreca F, Vanderah TW, Hruby VJ. Effect of anchoring 4-anilidopiperidines to opioid peptides. Bioorg. Med. Chem. Lett. 2013;23:3434–3437.
  8. Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2013;28:92–107.
  9. Edelmayer RM, Le LN, Yan J, Wei X, Nassini R, Materazzi S, Preti D, Appendino G, Geppetti P, Dodick DW, Vanderah TW, Porreca F, Dussor G. Activation of TRPA1 on dural afferents: a potential mechanism of headache pain. Pain. 2012;153:1949–1958.
  10. De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L. Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression. Neurosci. Lett. 2012;521:40–45.

Academic Information

Neuropharmacology, University of Colorado, Denver, Co
Pharmacology and Toxicology, University of Arizona, Tucson, AZ
Undergraduate School: 
BS, Molecular and Cellular biology, University of Arizona, Tucson, AZ